TY - JOUR
T1 - Development of Safe and Potent Oil-in-Water Emulsion of Paclitaxel to Treat Peritoneal Dissemination
AU - Ogawara, Ken-ichi
AU - Fukuoka, Yoshiko
AU - Yoshizawa, Yuta
AU - Kimura, Toshikiro
AU - Higaki, Kazutaka
N1 - Funding Information:
This research was supported in part by the grant-in-aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KO). The funding source was not involved in the study design, analysis, or interpretation of data.
Publisher Copyright:
© 2017 American Pharmacists Association®
PY - 2017/4/1
Y1 - 2017/4/1
N2 - To develop a safer and more potent paclitaxel (PTX) formulation, we prepared various oil-in-water emulsions by using egg phosphatidylcholine, Tween 80, and a mixture of triglycerides with different fatty acid chain lengths as the cosurfactant, surfactant, and oil phase component, respectively. The mean particle diameters of the PTX-emulsions prepared were around 100 nm. The PTX-emulsions did not provoke histamine release from rat mast cells and did not show any significant hemolytic activity, suggesting that PTX-emulsions are biocompatible. In vivo antitumor activity after single intraperitoneal injection of PTX-emulsions to ascites tumor-bearing mice revealed that the formulation containing tricaproin and triacetin (3:1, wt/wt, PTX-emulsion B) significantly prolonged the survival time and suppressed the accumulation of ascites fluid. Two distinct in vitro release studies showed that the release of PTX from emulsion B was significantly faster than those from other preparations. These results indicate that the adequately sustained PTX release would lead to potent in vivo antitumor activity and that PTX-emulsion B would offer an alternative approach to treat peritoneal dissemination.
AB - To develop a safer and more potent paclitaxel (PTX) formulation, we prepared various oil-in-water emulsions by using egg phosphatidylcholine, Tween 80, and a mixture of triglycerides with different fatty acid chain lengths as the cosurfactant, surfactant, and oil phase component, respectively. The mean particle diameters of the PTX-emulsions prepared were around 100 nm. The PTX-emulsions did not provoke histamine release from rat mast cells and did not show any significant hemolytic activity, suggesting that PTX-emulsions are biocompatible. In vivo antitumor activity after single intraperitoneal injection of PTX-emulsions to ascites tumor-bearing mice revealed that the formulation containing tricaproin and triacetin (3:1, wt/wt, PTX-emulsion B) significantly prolonged the survival time and suppressed the accumulation of ascites fluid. Two distinct in vitro release studies showed that the release of PTX from emulsion B was significantly faster than those from other preparations. These results indicate that the adequately sustained PTX release would lead to potent in vivo antitumor activity and that PTX-emulsion B would offer an alternative approach to treat peritoneal dissemination.
KW - biocompatibility
KW - cancer
KW - controlled release/delivery
KW - drug delivery
KW - emulsion/microemulsion
KW - surfactants
UR - http://www.scopus.com/inward/record.url?scp=85011031832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011031832&partnerID=8YFLogxK
U2 - 10.1016/j.xphs.2016.12.029
DO - 10.1016/j.xphs.2016.12.029
M3 - Article
C2 - 28063824
AN - SCOPUS:85011031832
SN - 0022-3549
VL - 106
SP - 1143
EP - 1148
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
IS - 4
ER -